Prognostic evaluation of glycogen synthase kinase 3A (GSK3A) mRNA expression in colon cancer patients

Neha Sylvia Walter, Jasmeet Kaur

Article ID: 6804
Vol 8, Issue 2, 2024

VIEWS - 1838 (Abstract)

Abstract


Introduction: GSK3, a multifunctional serine/threonine kinase regulates cell-cycle progression, differentiation and apoptosis and its inhibition can have a tumor suppressor/promoter effect, depending on the cell type. There are conflicting reports of GSK3 in cell growth, but most studies have focused on GSK3β and very few on GSK3α in cancer. GSK3α regulates proliferation of melanoma and pancreatic and colon cancer cells, but the predictive role of GSK3A is not known in colon cancer. Material and methods: The prognostic role of GSK3A was assessed in colon cancer patients employing Kaplan-Meier plotter (KM plotter) database. Online ROC plotter tool was used to compare the GSK3A gene expression in colorectal cancer patients receiving any form of chemotherapy. Results: Current results show that higher GSK3A mRNA expression is significantly related to poorer Relapse Free Survival (RFS) in colon cancer patients. Assessment of GSK3A mRNA for different clinicopathological features like clinical stages, TP53 mutation, stage T and stage N highlighted the critical prognostic value of GSK3A mRNA in colon cancer. Discussion and conclusion: GSK3A will help to better predict colon cancer prognosis and to develop better treatment strategies for colon cancer patients and will be beneficial in combating the heterogeneity and complexity of colon cancer.


Keywords


colon cancer; GSK3A; relapse-free survival; Kaplan-Meier plotter; ROC plotter

Full Text:

PDF


References


Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018; 68(6): 394-424. doi: 10.3322/caac.21492 Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. The EMBO Journal. 1990; 9(8): 2431-2438. doi: 10.1002/j.1460-2075.1990.tb07419.x Welsh GI, Proud CG. Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochemical Journal. 1993; 294(3): 625-629. doi: 10.1042/bj2940625 Cohen P, Frame S. The renaissance of GSK3. Nature Reviews Molecular Cell Biology. 2001; 2(10): 769-776. doi: 10.1038/35096075 Duda P, Akula SM, Abrams SL, et al. Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. Cells. 2020; 9(5): 1110. doi: 10.3390/cells9051110 Jope RS, Johnson GVW. The glamour and gloom of glycogen synthase kinase-3. Trends in Biochemical Sciences. 2004; 29(2): 95-102. doi: 10.1016/j.tibs.2003.12.004 Medina M, Castro A. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr Opin Drug Discov Devel. 2008; 11:533-43. Garcea G, Manson M, Neal C, et al. Glycogen Synthase Kinase-3 Beta; A New Target in Pancreatic Cancer? Current Cancer Drug Targets. 2007; 7(3): 209-215. doi: 10.2174/156800907780618266 Obligado SH, Ibraghimov-Beskrovnaya O, Zuk A, et al. CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases. Kidney International. 2008; 73(6): 684-690. doi: 10.1038/sj.ki.5002731 Dewhurst S, Maggirwar SB, Schifitto G, et al. Glycogen Synthase Kinase 3 Beta (GSK-3β) as a Therapeutic Target in NeuroAIDS. Journal of Neuroimmune Pharmacology. 2006; 2(1): 93-96. doi: 10.1007/s11481-006-9051-1 MacAulay K, Doble BW, Patel S, et al. Glycogen Synthase Kinase 3α-Specific Regulation of Murine Hepatic Glycogen Metabolism. Cell Metabolism. 2007; 6(4): 329-337. doi: 10.1016/j.cmet.2007.08.013 Piazza F, Manni S, Tubi LQ, et al. Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. BMC Cancer. 2010; 10(1). doi: 10.1186/1471-2407-10-526 Wilson W, Baldwin AS. Maintenance of Constitutive IκB Kinase Activity by Glycogen Synthase Kinase-3α/β in Pancreatic Cancer. Cancer Research. 2008; 68(19): 8156-8163. doi: 10.1158/0008-5472.can-08-1061 Forde JE, Dale TC. Glycogen synthase kinase 3: A key regulator of cellular fate. Cellular and Molecular Life Sciences. 2007; 64(15): 1930-1944. doi: 10.1007/s00018-007-7045-7 Liang MH, Chuang DM. Differential Roles of Glycogen Synthase Kinase-3 Isoforms in the Regulation of Transcriptional Activation. Journal of Biological Chemistry. 2006; 281(41): 30479-30484. doi: 10.1074/jbc.m607468200 Hoeflich KP, Luo J, Rubie EA, et al. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature. 2000; 406(6791): 86-90. doi: 10.1038/35017574 Borden BA, Baca Y, Xiu J, et al. The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer. Molecular Cancer Therapeutics. 2021; 20(1): 183-190. doi: 10.1158/1535-7163.mct-20-0497 Grassilli E, Ianzano L, Bonomo S, et al. GSK3A Is Redundant with GSK3B in Modulating Drug Resistance and Chemotherapy-Induced Necroptosis. Condorelli G, ed. PLoS ONE. 2014; 9(7): e100947. doi: 10.1371/journal.pone.0100947 Gao L, Lu Y, Chen HN, et al. Deciphering the Clinical Significance and Kinase Functions of GSK3α in Colon Cancer by Proteomics and Phosphoproteomics. Molecular & Cellular Proteomics. 2023; 22(5): 100545. doi: 10.1016/j.mcpro.2023.100545 Guil-Luna S, Rivas-Crespo A, Navarrete-Sirvent C, et al. Clinical significance of glycogen synthase kinase 3 (GSK-3) expression and tumor budding grade in colorectal cancer: Implications for targeted therapy. Biomedicine & Pharmacotherapy. 2023; 167: 115592. doi: 10.1016/j.biopha.2023.115592 Cao X, Wu W, Wang D, et al. Glycogen synthase kinase GSK3α promotes tumorigenesis by activating HIF1/VEGFA signaling pathway in NSCLC tumor. Cell Communication and Signaling. 2022; 20(1). doi: 10.1186/s12964-022-00825-3 Kaur J. Prognostic Effect of Glycogen Synthase Kinase 3A (GSK3A) mRNA Expression in Breast Cancer Patients. American Journal of Biomedical Sciences. Published online April 2022: 58-71. doi: 10.5099/aj220200058 Kovács SA, Fekete JT, Győrffy B. Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors. Acta Pharmacologica Sinica. 2023; 44(9): 1879-1889. doi: 10.1038/s41401-023-01079-6 Győrffy B. Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. GeroScience. 2023; 45(3): 1889-1898. doi: 10.1007/s11357-023-00742-4 Liu H. Microarray probes and probe sets. Frontiers in Bioscience. 2010; E2(1): 325-338. doi: 10.2741/e93 Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA: A Cancer Journal for Clinicians. 2020; 70(3): 145-164. doi: 10.3322/caac.21601 Ansa B, Coughlin S, Alema-Mensah E, et al. Evaluation of Colorectal Cancer Incidence Trends in the United States (2000–2014). Journal of Clinical Medicine. 2018; 7(2): 22. doi: 10.3390/jcm7020022 Ali A, Hoeflich KP, Woodgett JR. Glycogen Synthase Kinase-3: Properties, Functions, and Regulation. Chemical Reviews. 2001; 101(8): 2527-2540. doi: 10.1021/cr000110o Luo J. Glycogen synthase kinase 3β (GSK3β) in tumorigenesis and cancer chemotherapy. Cancer Letters. 2009; 273(2): 194-200. doi: 10.1016/j.canlet.2008.05.045 McCubrey JA, Davis NM, Abrams SL, et al. Diverse roles of GSK-3: Tumor promoter–tumor suppressor, target in cancer therapy. Advances in Biological Regulation. 2014; 54: 176-196. doi: 10.1016/j.jbior.2013.09.013 McCubrey JA, Fitzgerald TL, Yang LV, et al. Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. Oncotarget. 2016; 8(8): 14221-14250. doi: 10.18632/oncotarget.13991 Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. Journal of Cell Science. 2003; 116(7): 1175-1186. doi: 10.1242/jcs.00384 Vidri RJ, Fitzgerald TL. GSK-3: An important kinase in colon and pancreatic cancers. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2020; 1867(4): 118626. doi: 10.1016/j.bbamcr.2019.118626 Valvezan AJ, Zhang F, Diehl JA, et al. Adenomatous Polyposis Coli (APC) Regulates Multiple Signaling Pathways by Enhancing Glycogen Synthase Kinase-3 (GSK-3) Activity. Journal of Biological Chemistry. 2012; 287(6): 3823-3832. doi: 10.1074/jbc.m111.323337 Shakoori A, Ougolkov A, Yu ZW, et al. Deregulated GSK3β activity in colorectal cancer: Its association with tumor cell survival and proliferation. Biochemical and Biophysical Research Communications. 2005; 334(4): 1365-1373. doi: 10.1016/j.bbrc.2005.07.041 Ougolkov AV, Fernandez-Zapico ME, Bilim VN, et al. Aberrant Nuclear Accumulation of Glycogen Synthase Kinase-3β in Human Pancreatic Cancer: Association with Kinase Activity and Tumor Dedifferentiation. Clinical Cancer Research. 2006; 12(17): 5074-5081. doi: 10.1158/1078-0432.ccr-06-0196 Ougolkov AV, Bone ND, Fernandez-Zapico ME, et al. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor κB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood. 2007; 110(2): 735-742. doi: 10.1182/blood-2006-12-060947 Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, et al. Inactivation of glycogen synthase kinase-3β, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Molecular Cancer Therapeutics. 2007; 6(3): 1151-1158. doi: 10.1158/1535-7163.mct-06-0665 Adler JT, Cook M, Luo Y, et al. Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3β. Molecular Cancer Therapeutics. 2009; 8(4): 914-920. doi: 10.1158/1535-7163.mct-08-0712 Carter YM, Kunnimalaiyaan S, Chen H, et al. Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. Cancer Biology & Therapy. 2014; 15(5): 510-515. doi: 10.4161/cbt.28015 Ougolkov AV, Fernandez-Zapico ME, Savoy DN, et al. Glycogen Synthase Kinase-3β Participates in Nuclear Factor κB–Mediated Gene Transcription and Cell Survival in Pancreatic Cancer Cells. Cancer Research. 2005; 65(6): 2076-2081. doi: 10.1158/0008-5472.can-04-3642 Kunnimalaiyaan S, Clark Gamblin T, Kunnimalaiyaan M. Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression. HPB. 2015; 17(9): 770-776. doi: 10.1111/hpb.12442 Thapa R, Gupta G, Bhat AA, et al. A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies. International Journal of Biological Macromolecules. 2023; 253: 127375. doi: 10.1016/j.ijbiomac.2023.127375 Sahin I, Eturi A, De Souza A, et al. Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses. Cancer Biology & Therapy. 2019; 20(8): 1047-1056. doi: 10.1080/15384047.2019.1595283 Augello G, Emma MR, Cusimano A, et al. The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment. Cells. 2020; 9(6): 1427. doi: 10.3390/cells9061427 Walz A, Ugolkov A, Chandra S, et al. Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer. Clinical Cancer Research. 2017; 23(8): 1891-1897. doi: 10.1158/1078-0432.ccr-15-2240 Madhunapantula SV, Sharma A, Gowda R, et al. Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma. Pigment Cell & Melanoma Research. 2013; 26(6): 886-899. doi: 10.1111/pcmr.12156 Sharma A, Sharma AK, Madhunapantula SV, et al. Targeting Akt3 Signaling in Malignant Melanoma Using Isoselenocyanates. Clinical Cancer Research. 2009; 15(5): 1674-1685. doi: 10.1158/1078-0432.ccr-08-2214 Nakayama M, Oshima M. Mutant p53 in colon cancer. Journal of Molecular Cell Biology. 2018; 11(4): 267-276. doi: 10.1093/jmcb/mjy075 Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nature Reviews Cancer. 2007; 7(4): 295-308. doi: 10.1038/nrc2109 Dinu D, Dobre M, Panaitescu E. et al. Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study. J Med Life. 2014; 7: 581-7. Caputo F, Santini C, Bardasi C, et al. BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights. International Journal of Molecular Sciences. 2019; 20(21): 5369. doi: 10.3390/ijms20215369 Tejpar S, Bertagnolli M, Bosman F, et al. Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery. The Oncologist. 2010; 15(4): 390-404. doi: 10.1634/theoncologist.2009-0233 Neumann JHL, Jung A, Kirchner T. Molekulare Pathologie des kolorektalen Karzinoms. Der Pathologe. 2015; 36(2): 137-144. doi: 10.1007/s00292-015-0005-3 Zeinalian M, Hashemzadeh-Chaleshtori M, Salehi R, Emami MH. Clinical Aspects of Microsatellite Instability Testing in Colorectal Cancer. Adv Biomed Res. 2018; 7:28. doi: 10.4103/abr.abr_185_16. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nature Medicine. 2015; 21(11): 1350-1356. doi: 10.1038/nm.3967 Peng Z, Ji Z, Mei F, et al. Lithium Inhibits Tumorigenic Potential of PDA Cells through Targeting Hedgehog-GLI Signaling Pathway. Xie J, ed. PLoS ONE. 2013; 8(4): e61457. doi: 10.1371/journal.pone.0061457 Acikgoz E, Güler G, Camlar M, et al. Glycogen synthase kinase-3 inhibition in glioblastoma multiforme cells induces apoptosis, cell cycle arrest and changing biomolecular structure. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2019; 209: 150-164. doi: 10.1016/j.saa.2018.10.036 Park R, Coveler AL, Cavalcante L, et al. GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties. Biology. 2021; 10(7): 610. doi: 10.3390/biology10070610 Schrecengost RS, Green CL, Zhuang Y, et al. In Vitro and In Vivo Antitumor and Anti-Inflammatory Capabilities of the Novel GSK3 and CDK9 Inhibitor ABC1183. Journal of Pharmacology and Experimental Therapeutics. 2018; 365(1): 107-116. doi: 10.1124/jpet.117.245738



DOI: https://doi.org/10.24294/ti.v8.i2.6804

Refbacks

  • There are currently no refbacks.


Copyright (c) 2024 Neha Sylvia Walter, Jasmeet Kaur

License URL: https://creativecommons.org/licenses/by/4.0/

This site is licensed under a Creative Commons Attribution 4.0 International License.